Diet drug, heart valve link bolstered by studies

Article Abstract:

The decision by the Food and Drug Administration in asking American Home Products Corp. to withdraw Redux and fenfluramine from the market last year has been backed up by further studies which demonstrate a conclusive link between the diet drugs and heart-valve leaks, according to a new report by the New England Journal of Medicine. But the new new research studies have shown that the adverse side-effects only affect less than 30% of users of the controversial diet pills. The maker of Redux, Interneuron Pharmaceuticals Inc., has recently negotiated a $100 million agreement to settle lawsuits stemming from the drug's use.

Comment:

Has participated in studies showing a conclusive link between the diet drugs, Redux and fenfluramine, and heart-valve leaks

Product information, Company Planning/Goals, Appetite Suppressants, Appetite depressants, Wyeth, Article

---

Cephalon receives marketing approval for Provigil medication for narcolepsy

Article Abstract:

Cephalon Inc. got its first U.S. drug approval from the FDA, for Provigil that treats narcolepsy. Provigil's generic name is modafinil and it is the first non-amphetamine drug for this use. The new drug is expected to sell about $100 million per year once pricing is set and it is in the pipeline for doctors to prescribe. Advantages of Provigil over amphetamines are that the drug more narrowly targets the parts of the brain needed to stimulate wakefulness; also, it won't have the addictive qualities. Myotrophin, a drug to treat Lou Gehrig's disease, would probably have been a more profitable drug for the company.

Comment:

Company has FDA approval to sell drug that treats narcolepsy

Marketing procedures, New Products/Services, Pharmaceutical preparations, Central Nervous System Prep, Care and treatment, Drugs, Pharmaceutical industry, Marketing, Abstract, Central nervous system agents, Narcolepsy, Cephalon Inc., CEPH

---

Similar abstracts:

• Abstracts: Unbundling Microsoft: U.S. judge rules the issue is marketing, and for that, old antitrust laws apply. U.S. reviews a bid made by Microsoft; competition an issue in offer to buy WebTV
• Abstracts: Role of prior affect and sensory cues on consumers' affective and cognitive responses and overall perceptions of quality
• Abstracts: FDA gets a cautious recommendation to approve vaccine for Lyme disease. FDA rules dietary supplement dupes cholesterol drug, raising legal issues
• Abstracts: IBM is ending Olympics deal in cost dispute. IBM and Equifax join forces to market certification for Internet transactions
• Abstracts: New proposal would alter stock sales to employees. Lawsuits by rivals accuse textile maker of corporate espionage

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.